title: Benefit of radiation boost after whole-breast radiotherapy.
abstract: OBJECTIVE
  To determine whether a boost to the tumor bed after breast-conserving surgery (BCS) and radiotherapy (RT) to the whole breast affects local control and disease-free survival.
  
  
  METHODS
  A total of 1,138 patients with pT1 to pT2 breast cancer underwent adjuvant RT at the University of Florence. We analyzed only patients with a minimum follow-up of 1 year (range, 1-20 years), with negative surgical margins. The median age of the patient population was 52.0 years (+/-7.9 years). The breast cancer relapse incidence probability was estimated by the Kaplan-Meier method, and differences between patient subgroups were compared by the log rank test. Cox regression models were used to evaluate the risk of breast cancer relapse.
  
  
  RESULTS
  On univariate survival analysis, boost to the tumor bed reduced breast cancer recurrence (p < 0.0001). Age and tamoxifen also significantly reduced breast cancer relapse (p = 0.01 and p = 0.014, respectively). On multivariate analysis, the boost and the medium age (45-60 years) were found to be inversely related to breast cancer relapse (hazard ratio [HR], 0.27; 95% confidence interval [95% CI], 0.14-0.52, and HR 0.61; 95% CI, 0.37-0.99, respectively). The effect of the boost was more evident in younger patients (HR, 0.15 and 95% CI, 0.03-0.66 for patients <45 years of age; and HR, 0.31 and 95% CI, 0.13-0.71 for patients 45-60 years) on multivariate analyses stratified by age, although it was not a significant predictor in women older than 60 years.
  
  
  CONCLUSIONS
  Our results suggest that boost to the tumor bed reduces breast cancer relapse and is more effective in younger patients.
authors.affiliation: Radiotherapy Unit, University of Florence, Florence, Italy. l.livi@dfc.unifi.it
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Livi
authors.forename: Simona
authors.initials: S
authors.lastname: Borghesi
authors.forename: Calogero
authors.initials: C
authors.lastname: Saieva
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Fambrini
authors.forename: Alberto
authors.initials: A
authors.lastname: Iannalfi
authors.forename: Daniela
authors.initials: D
authors.lastname: Greto
authors.forename: Fabiola
authors.initials: F
authors.lastname: Paiar
authors.forename: Silvia
authors.initials: S
authors.lastname: Scoccianti
authors.forename: Gabriele
authors.initials: G
authors.lastname: Simontacchi
authors.forename: Simonetta
authors.initials: S
authors.lastname: Bianchi
authors.forename: Luigi
authors.initials: L
authors.lastname: Cataliotti
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Biti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology / Q000517:prevention & control / Q000532:radiotherapy* / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D053208:Kaplan-Meier Estimate; D015412:Mastectomy, Segmental; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D016016:Proportional Hazards Models; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D019233:Retreatment; D012189:Retrospective Studies
chemical_list: D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate